Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Kaposi's sarcoma
ADR ID BADD_A02437
ADR Hierarchy
11      Infections and infestations
11.05      Viral infectious disorders
11.05.17      Retroviral infections
11.05.17.001      Kaposi's sarcoma
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.33      Soft tissue neoplasms malignant and unspecified
16.33.02      Kaposi's sarcomas
16.33.02.001      Kaposi's sarcoma
Description A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. [MeSH]
MedDRA Code 10023284
MeSH ID D012514
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Allograft-associated hemorrhagic sarcoma | Endemic type hemorrhagic sarcoma | Idiopathic haemorrhagic sarcoma | Kaposi's sarcoma | Kaposi's sarcoma NOS | Kaposi's sarcoma, gastrointestinal sites | Kaposi's sarcoma, lung | Kaposi's sarcoma, lymph nodes | Kaposi's sarcoma, other specified sites | Kaposi's sarcoma, palate | Kaposi's sarcoma, skin | Kaposi's sarcoma, soft tissue | Kaposi's sarcoma, unspecified | Multiple haemorrhagic sarcoma | Multiple hemorrhagic sarcoma | Multiple idiopathic hemorrhagic sarcoma | Idiopathic hemorrhagic sarcoma | Allograft-associated haemorrhagic sarcoma | Endemic type haemorrhagic sarcoma | Multiple idiopathic haemorrhagic sarcoma | Sarcoma, Kaposi | Kaposi's Sarcoma | Kaposis Sarcoma | Sarcoma, Kaposi's | Multiple Idiopathic Pigmented Hemangiosarcoma | Kaposi Sarcoma
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00036Acitretin0.001250%
BADD_D00195Azathioprine0.001410%
BADD_D00230Bendamustine0.000112%
BADD_D00490Clobetasol propionate0.003735%
BADD_D00551Cyclosporine0.000111%
BADD_D00704Dolutegravir sodium0.000565%
BADD_D00723Doxorubicin0.000392%
BADD_D00749Efavirenz0.005505%
BADD_D00854Etoposide0.000336%
BADD_D00858Everolimus--
BADD_D00914Fludarabine0.000112%
BADD_D01136Imatinib0.000448%
BADD_D01142Imiquimod0.000439%
BADD_D01242Lamivudine0.001012%
BADD_D01252Leflunomide0.000643%
BADD_D01508Mycophenolic acid--
BADD_D01633Oxaliplatin0.000168%
BADD_D01798Pomalidomide0.000651%
BADD_D01804Posaconazole--
BADD_D01831Prednisolone0.000262%
BADD_D01834Prednisone0.000166%
BADD_D01835Pregabalin0.000052%
BADD_D01881Pyridostigmine0.002125%
BADD_D01892Quinaprilat0.005438%
BADD_D01905Raltegravir0.001648%
BADD_D01906Raltegravir potassium--
BADD_D01953Rituximab--
BADD_D01978Ruxolitinib0.000137%
BADD_D01989Saquinavir mesylate--
BADD_D02028Sirolimus0.000201%
The 1th Page    1 2    Next   Last    Total 2 Pages